蒙脱石散治疗肠易激综合征(IBS)的临床疗效和安全性  

Clinical Efficacy And Safety of Montmorillonite Powder in the Treatment of Irritable Bowel Syndrome (IBS)

作　　者：杨嘉麟 潘立 Yang Jialin;Pan Li(Wuhan Puren Hospital,Wuhan Hubei 430080,China;Department of Consultation The Central Hospital of Wuhan,Wuhan Hubei 430014,China)

机构地区：[1]武汉市普仁医院,湖北武汉430080 [2]武汉市中心医院导诊部,湖北武汉430014

出　　处：《生命科学仪器》2024年第6期175-177,共3页Life Science Instruments

摘　　要：目的研究对肠易激综合征(IBS)患者采用蒙脱石散治疗的疗效及安全性。方法选择2017年5月至2022年5月期间于医院治疗的60例IBS患者,根据治疗方案的不同分为对照组和研究组,每组30例。对照组接受丽珠肠乐药物治疗,研究组接受蒙脱石散治疗。比较两组患者的疗效及安全性。结果研究组治疗总有效率高于对照组,P<0.05;研究组不良反应发生率低于对照组,P<0.05;治疗前,两组胃肠激素指标对比,P>0.05;治疗后,研究组胃肠激素指标均低于对照组,P<0.05。治疗前,两组症状分级对比,P>0.05;治疗后,研究组症状分级低于对照组,P<0.05。结论蒙脱石散治疗IBS患者可提升用药疗效及安全性,使患者胃肠症状逐渐改善,胃肠功能逐步恢复。Objective:To study the efficacy and safety of montmorillonite powder in the treatment of irritable bowel syndrome(IBS).Methods:Sixty patients with IBS treated in the hospital from May 2017 to May 2022 were selected and divided into control group and study group according to different treatment schemes,with 30 patients in each group.The control group was treated with Livzon Changle,while the study group was treated with montmorillonite powder.The efficacy and safety of the two groups were compared.Results:The total effective rate of the study group was higher than that of the control group,P<0.05.The incidence of adverse reactions in the study group was lower than that in the control group,P<0.05;Before treatment,the gastrointestinal hormone indexes of the two groups were compared,P>0.05;After treatment,the indexes of gastrointestinal hormones in the study group were lower than those in the control group,P<0.05.Before treatment,the symptoms of the two groups were graded and compared,P>0.05;After treatment,the symptom grade of the study group was lower than that of the control group,P<0.05.Conclusion:Montmorillonite powder can improve the efficacy and safety of medication for IBS patients,and gradually improve gastrointestinal symptoms and gastrointestinal function.

关 键 词：蒙脱石散 肠易激综合征 胃肠激素 症状分级 

分 类 号：R256.3[医药卫生—中医内科学]